Telix Pharmaceuticals Limited Investor Relations Material
Latest events
H1 2024
Telix Pharmaceuticals Limited
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Telix Pharmaceuticals Limited
Access all reports
Telix Pharmaceuticals Limited is a global biopharmaceutical company at the commercial stage, primarily engaged in developing diagnostic and therapeutic products using targeted radiation for cancer and rare diseases. The company is pioneering in the field of radiopharmaceuticals, aiming to advance precision medicine through its innovative approach. Telix's product development focuses on molecularly targeted radiation (MTR) products that seek to improve patient outcomes by precisely targeting diseased cells, thereby minimizing the impact on healthy tissues. Its research pipeline includes a range of diagnostic and therapeutic agents for conditions such as prostate cancer, kidney cancer, glioblastoma (brain cancer), and hematologic cancers, as well as bone marrow conditioning for rare diseases. TThe company is headquartered in North Melbourne, Australia, and its shares are listed on the ASX.
Key slides for Telix Pharmaceuticals Limited
H1 2024
Telix Pharmaceuticals Limited
H1 2024
Telix Pharmaceuticals Limited
Latest articles
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
TLX
Country
🇦🇺 Australia